These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 10506637)

  • 61. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
    Wolfson AH; Brady MF; Rocereto T; Mannel RS; Lee YC; Futoran RJ; Cohn DE; Ioffe OB
    Gynecol Oncol; 2007 Nov; 107(2):177-85. PubMed ID: 17822748
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Toxicity antagonists in cancer therapy.
    Trotti A
    Curr Opin Oncol; 1997 Nov; 9(6):569-78. PubMed ID: 9370079
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The potential influence of cell protectors for dose escalation in cancer therapy: an analysis of amifostine.
    McCumber LM
    Med Dosim; 2004; 29(2):139-43. PubMed ID: 15191764
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
    Tonkin K; Bates M; Lieu D; Arundell E; Williamson T; Zagari M
    Can J Oncol; 1996 Nov; 6(2):458-73. PubMed ID: 12056098
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
    Lopez M
    Clin Ter; 1999; 150(1):37-49. PubMed ID: 10367544
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
    Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Amifostine in clinical oncology: current use and future applications.
    Koukourakis MI
    Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
    Basser RL; Sobol MM; Duggan G; Cebon J; Rosenthal MA; Mihaly G; Green MD
    J Clin Oncol; 1994 Aug; 12(8):1659-66. PubMed ID: 8040678
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
    Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
    Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
    [TBL] [Abstract][Full Text] [Related]  

  • 73. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
    Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
    Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dexrazoxane as a cardioprotectant in children receiving anthracyclines.
    Sepe DM; Ginsberg JP; Balis FM
    Oncologist; 2010; 15(11):1220-6. PubMed ID: 21051660
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.
    Mell LK; Movsas B
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1341-50. PubMed ID: 18798703
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Amifostine: is there evidence of tumor protection?
    Koukourakis MI
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):18-30. PubMed ID: 14727237
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment-related esophagitis.
    Werner-Wasik M
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S60-6. PubMed ID: 16015537
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Amifostine: current and future applications in cytoprotection].
    Lenoble M
    Bull Cancer; 1996 Sep; 83(9):773-87. PubMed ID: 8952658
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique.
    Hellmann K
    J Clin Oncol; 2000 May; 18(9):2004-6. PubMed ID: 10784645
    [No Abstract]   [Full Text] [Related]  

  • 80. Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells.
    Zaki EL; Springate JE; Taub M
    Toxicol In Vitro; 2003 Aug; 17(4):397-402. PubMed ID: 12849722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.